title: Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.
abstract: BACKGROUND
  Abnormal serum lipid profiles have been noted in patients with chronic hepatitis C virus (HCV) infection. Moreover, many reports suggest that serum lipoprotein profiles are more profoundly distorted in patients with HCV G1b infection who have an unfavorable response to pegylated interferon (peg-IFN) plus ribavirin (RBV) combination therapy. However, after the discovery of single nucleotide polymorphisms near the IL28B gene (rs8099917 and rs12979860) as potent predictive factors affecting the response to peg-IFN plus RBV, lipid factors are thought to be confounding factors.
  
  
  OBJECTIVE
  To re-examine the significance of lipoprotein profiles on virological response to peg-IFN plus RBV combination therapy in patients with chronic HCV G1b infection, we examined cholesterol and triglyceride concentrations in each lipoprotein fraction separated by high performance liquid chromatography.
  
  
  METHODS
  Lipoprotein profiles were examined using fasting sera from 108 patients infected with HCV G1b who had chronic hepatitis, as determined by liver biopsy. Results of lipoprotein profiles and clinical data, including IL28B genotype and amino acid substitution at aa70 of HCV G1b, were compared between patients with a sustained virological response (SVR) and non-SVR or a non-virological response (NVR) and virological responses other than NVR (non-NVR). In addition, significant predictive factors independently associated with virological response to peg-IFNα-2b plus RBV were determined by logistic regression analysis.
  
  
  RESULTS
  An increased ratio of cholesterol/triglyceride in very low-density lipoprotein (odds ratio (OR) 3.03; 95% confidence interval (CI) 1.01-9.44) along with a major genotype of rs8099917 (OR 9.09; 95% CI 2.94-33.33), were independent predictive factors for SVR. In contrast, lipid factors were not elucidated as independent predictive factors for NVR.
  
  
  CONCLUSIONS
  Examination of the fasting lipid profile has clinical importance in predicting the efficacy of peg-IFN-α-2b plus RBV combination therapy for patients with HCV G1b even after the discovery of the IL28 genotype as a potent predictive factor.
authors: Department of Gastroenterology and Hepatology, Jikei University School of Medicine, Tokyo, Japan.
authors: Yoshio
authors: Y
authors: Aizawa
authors: Noritomo
authors: N
authors: Shimada
authors: Hiroshi
authors: H
authors: Abe
authors: Nobuyoshi
authors: N
authors: Seki
authors: Yuta
authors: Y
authors: Aida
authors: Haruya
authors: H
authors: Ishiguro
authors: Makiko
authors: M
authors: Ika
authors: Keizo
authors: K
authors: Kato
authors: Akihito
authors: A
authors: Tsubota
keywords: Chromatography, High Pressure Liquid; Hepatitis C; Lipoproteins; Lipoproteins VLDL; Ribavirin
references: J Gastroenterol Hepatol. 2008 Apr;23(4):586-91
references: 17498221
references: Clin Infect Dis. 2009 Apr 15;48(8):1152-9
references: 19275492
references: J Viral Hepat. 2008 Oct;15(10):740-6
references: 18482281
references: Hepatology. 1996 Aug;24(2):289-93
references: 8690394
references: J Gen Virol. 2009 May;90(Pt 5):1055-1070
references: 19264629
references: Trends Microbiol. 2011 Jul;19(7):368-75
references: 21530270
references: Clin Chem. 1972 Jun;18(6):499-502
references: 4337382
references: J Viral Hepat. 2010 Apr;17(4):274-9
references: 19708862
references: Diabetes. 1998 May;47(5):779-87
references: 9588450
references: Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):10-6
references: 22959093
references: Trends Endocrinol Metab. 2010 Jan;21(1):33-40
references: 19854061
references: Hepatology. 2012 Jul;56(1):39-48
references: 22290760
references: Mol Cell Biochem. 2012 Jan;360(1-2):9-14
references: 21879313
references: Hepatology. 2010 Jun;51(6):1904-11
references: 20235331
references: Nature. 2009 Sep 17;461(7262):399-401
references: 19684573
references: Hepatology. 2006 Aug;44(2):335-40
references: 16871569
references: J Hepatol. 2007 Mar;46(3):403-10
references: 17126448
references: Aliment Pharmacol Ther. 2009 Jun 15;29(12):1282-90
references: 19392865
references: J Lipid Res. 2002 May;43(5):805-14
references: 11971952
references: Hepatology. 2010 Sep;52(3):854-63
references: 20690192
references: Biochimie. 2013 Jan;95(1):96-102
references: 22884392
references: Science. 1968 Nov 22;162(3856):909-11
references: 5684497
references: Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5848-53
references: 17376867
references: Hepatology. 2009 Apr;49(4):1335-74
references: 19330875
references: J Viral Hepat. 2012 May;19(5):332-40
references: 22497812
references: Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):578-84
references: 15637308
references: Anal Biochem. 1968 Oct 24;25(1):347-62
references: 4178699
references: Am J Gastroenterol. 2009 Mar;104(3):598-604
references: 19262519
references: Biochimie. 2013 Jan;95(1):103-8
references: 22959067
references: Nat Genet. 2009 Oct;41(10):1105-9
references: 19749757
references: J Virol. 2006 Mar;80(5):2418-28
references: 16474148
references: Clin Biochem. 2009 Jan;42(1-2):114-7
references: 18996105